The global Infusion Pumps Market is projected to increase from USD 5.1 billion in 2025 to USD 5.4 billion in 2026, reaching USD 9.1 billion by 2036, according to Future Market Insights (FMI). The market is expected to expand at a compound annual growth rate (CAGR) of 5.4% between 2026 and 2036, creating an incremental opportunity of approximately USD 3.72 billion over the forecast period.

Demand is being supported by stricter patient-safety requirements, standardized clinical treatment protocols, and growing healthcare needs associated with aging populations and chronic conditions. Hospitals and outpatient facilities are increasingly prioritizing infusion systems that meet regulatory requirements, support consistent treatment delivery, and fit established clinical workflows.

Volumetric pumps are expected to account for 20.0% of product-type demand in 2026, while stationary pumps are projected to represent 65.0% of the modality segment. The United States is forecast to lead country-level growth with a 5.8% CAGR through 2036.

Request For a Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-859

The Short Version

·         Market outlook: The global infusion pumps market is projected to reach USD 9.1 billion by 2036.

·         Growth rate: FMI forecasts a 5.4% CAGR between 2026 and 2036.

·         Incremental opportunity: The market is expected to create approximately USD 3.72 billion in additional value during the forecast period.

·         Leading product type: Volumetric pumps are projected to hold a 20.0% share in 2026.

·         Leading modality: Stationary pumps are expected to account for 65.0% of modality demand.

·         Fastest-growing country: The United States is forecast to expand at a 5.8% CAGR.

·         Key market participants: Medtronic, Terumo Corporation, Smiths Group, MOOG, B. Braun, Fresenius Kabi, Insulet, ICU Medical, Baxter, and Becton Dickinson.

Three Numbers That Matter

USD 9.1 billion: The projected global market value by 2036, reflecting increasing demand for controlled drug and fluid delivery across healthcare settings.

20.0%: The expected 2026 share of volumetric pumps, highlighting their established role in institutional infusion therapy.

65.0%: The projected 2026 share of stationary pumps within the modality segment, reflecting the importance of hospital-based and other institutional procurement.

Why Is the Infusion Pumps Market Growing?

Infusion pumps support the controlled administration of fluids and medications across a wide range of clinical settings. Their use in chemotherapy, pediatric and neonatal care, analgesia, gastroenterology, hematology, and diabetes management makes them an important component of modern healthcare delivery.

Patient safety is a major factor shaping procurement decisions. Healthcare systems are placing greater emphasis on validated equipment, regulatory compliance, and standardized treatment protocols. Hospitals are also consolidating supplier panels and evaluating devices based on quality credentials, clinical performance, and lifecycle costs.

Demographic changes are adding to the demand outlook. Aging populations and the growing prevalence of chronic conditions are increasing the number of patients requiring ongoing treatment and medication administration. Meanwhile, expanding reimbursement frameworks and healthcare infrastructure investment in emerging economies are improving access to institutional care.

Where Growth Is Strongest

The United States is projected to record a 5.8% CAGR from 2026 to 2036, making it the fastest-growing country market listed by FMI. Mature equipment replacement cycles, regulatory compliance upgrades, and specification-driven procurement are supporting demand. Hospital networks and institutional buyers are prioritizing validated products that meet established quality and safety requirements.

The United Kingdom is forecast to expand at a 4.7% CAGR. Regulatory modernization, institutional procurement standardization, and continued healthcare infrastructure investment are expected to support demand. Manufacturers with established regulatory expertise and reliable supply arrangements may be better positioned to serve institutional buyers.

Germany is projected to register a 4.5% CAGR. Stringent product specifications, EU regulatory requirements, and demand from established healthcare and institutional procurement networks are expected to support the market.

Other country projections include Japan at 4.3% and France at 4.1%. Japan's outlook is supported by advanced manufacturing requirements and infrastructure replacement demand, while France benefits from institutional procurement modernization and EU compliance requirements.

Which Segments Are Shaping Demand?

Volumetric pumps are projected to account for 20.0% of product-type demand in 2026. Their broad clinical applicability and established role in institutional treatment protocols support their position. Other product categories include syringe pumps, small-volume pumps, ambulatory pumps, peristaltic pumps, cassette/piston pumps, implantable pumps, insulin pumps, enteral pumps, and patient-controlled analgesia (PCA) pumps.

By modality, stationary pumps are expected to represent 65.0% of demand in 2026. Institutional purchasing patterns and standardized clinical workflows underpin this segment's leading position.

The application landscape includes chemotherapy and oncology, pediatrics and neonatology, analgesia, gastroenterology, hematology, and diabetes. End users include hospitals, ambulatory surgical centers, home-care providers, and clinics. These segments create opportunities for manufacturers to develop portfolios addressing different treatment environments and patient requirements.

Who Is Moving: Competitive Landscape and Key Players

Competition in the infusion pumps market is influenced by product reliability, clinical validation, regulatory compliance, portfolio breadth, and distribution access. Manufacturers with established hospital relationships and the ability to meet institutional procurement requirements are positioned to compete for long-term supply agreements.

FMI identifies the following companies among the key market participants:

·         Medtronic Plc

·         Terumo Corporation

·         Smiths Group plc

·         MOOG Inc.

·         B. Braun Melsungen AG

·         Fresenius Kabi AG

·         Insulet Corporation

·         ICU Medical Inc.

·         Baxter International Inc.

·         Becton Dickinson and Company

·         CareFusion Corporation

·         Hospira Inc.

Medtronic holds a leading position in FMI's competitive assessment, supported by its broad product portfolio, clinical validation capabilities, and institutional distribution access. Terumo Corporation and Smiths Group also maintain competitive positions through specialized product offerings and regional regulatory expertise.

Other participants are building positions through focused product development, cost-competitive manufacturing, and expansion into specific clinical applications. Regulatory approval timelines, clinical validation requirements, and institutional procurement qualification cycles remain important barriers to market entry.

Where to Act and Where to Be Careful

Manufacturers can prioritize product reliability, regulatory compliance, and cost competitiveness across hospital and outpatient channels. Diversified portfolios that address different infusion requirements may help suppliers serve a wider range of clinical settings.

Emerging markets in South Asia and East Asia offer opportunities as healthcare infrastructure investment and insurance coverage expansion improve access to standardized treatment. However, supply-chain localization requirements in markets such as China and India may influence sourcing and manufacturing strategies.

Cost pressure remains a challenge, particularly in price-sensitive product categories. Clinical validation expenses and institutional qualification processes can also affect commercialization timelines. Suppliers should balance product differentiation with affordability, service support, and dependable regional distribution.

Access the Full Report: https://www.futuremarketinsights.com/reports/infusion-pumps-market

Analyst Perspective

FMI's market assessment indicates a shift from volume-led purchasing toward specification-driven procurement. Quality consistency, regulatory compliance, cost competitiveness, supply-chain resilience, and regional manufacturing presence are becoming important supplier-selection criteria. This is a summary of the report's analyst commentary, not a separately attributed quotation.

Questions for Your Next Planning Meeting

·         How can manufacturers strengthen product reliability and regulatory compliance?

·         Which infusion pump categories offer the strongest opportunities across hospital and outpatient care?

·         How will institutional procurement standardization influence supplier selection?

·         What investments are needed to improve regional manufacturing and supply-chain resilience?

·         Which country markets should manufacturers prioritize through 2036?

Related Reports:

·         Frozen Clinical Meal Market - https://www.futuremarketinsights.com/reports/frozen-clinical-meal-market

·         Long-COVID Nutrition Products Market - https://www.futuremarketinsights.com/reports/long-covid-nutrition-products-market

·         Neonatal Lipid Supplement Market - https://www.futuremarketinsights.com/reports/neonatal-lipid-supplement-market

About Future Market Insights (FMI)

Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.

For Press & Corporate Inquiries

Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075

For Sales – sales@futuremarketinsights.com
For Media – Rahul.singh@futuremarketinsights.com
For Web – https://www.futuremarketinsights.com